A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...
The mRNA vaccine works by targeting genetic mutations found in pancreatic cancer, alerting the immune system to recognize and ...
The concept of using vaccines to treat cancers has been around for several decades. A vaccine was first approved for prostate cancer in 2010, and another was approved in 2015 for melanoma. Since then, ...
Fueled by pandemic frustrations, populist parties are embracing anti-vaccine figures — in the U.S. and elsewhere.
In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.
A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...
CBS Boston on MSN21h
Pancreatic cancer vaccine shows promise, according to studyIn trials, a vaccine for pancreatic cancer developed by Sloan-Ketterin and BioNTech showed promise, but researchers say it is ...
The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...
"GMA" examines a preliminary study where a personalized mRNA vaccine showed promise in reducing the risk of pancreatic cancer ...
A personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery, according to a preliminary ...
Dr. Yuzhong Liu, an assistant chemistry professor at Scripps Research, was among three scientists granted $150,000 Wednesday ...
A lawyer for the plaintiff in the case said Merck agreed to halting the trial because his team feared that extensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results